Hybrid peptides having mixed substance P (NK1), neurokinin A (NK2) and bradykinin (BK2) antagonist properties.
Srivastava
V P
VP
Cortech, Inc., Denver, CO 80221, USA.
Goodfellow
V S
VS
Zuzack
J S
JS
Jones
S
S
Francis
M
M
Beckey
V E
VE
Whalley
E T
ET
D000818:Animals; D001920:Bradykinin / Q000037:antagonists & inhibitors*; D065168:Bradykinin Receptor Antagonists; D006168:Guinea Pigs; D006801:Humans; D007082:Ileum / Q000187:drug effects; D066298:In Vitro Techniques; D015394:Molecular Structure; D015288:Neurokinin A / Q000037:antagonists & inhibitors*; D064729:Neurokinin-1 Receptor Antagonists; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*; D011651:Pulmonary Artery / Q000187:drug effects; D011817:Rabbits; D043782:Receptor, Bradykinin B2; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors; D013329:Structure-Activity Relationship; D013373:Substance P / Q000037:antagonists & inhibitors*
D065168:Bradykinin Receptor Antagonists; D064729:Neurokinin-1 Receptor Antagonists; D009842:Oligopeptides; D043782:Receptor, Bradykinin B2; D018041:Receptors, Neurokinin-2; D013373:Substance P; D015288:Neurokinin A; D001920:Bradykinin